On October 19, 2026, the FDA granted accelerated approval to Jemperli (dostarlimab) — immunotherapy alone — for adults with stage II or III MSI-H/dMMR rectal cancer. In the AZUR-1 study, nearly half of patients had no detectable cancer a full year after treatment, and many avoided chemotherapy, radiation, and surgery. Here is what the news means, in plain language.